Novo Nordisk's 2024 earnings exceeded estimates ... A highlight was the approval of Alhemo for treating hemophilia A and B in several major markets, including the United States and the European ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug ... shows the logo of Novo Nordisk ...

Novo Nordisk's anti-TFPI antibody concizumab ... However, the two drugs are going after different indications. Alhemo is indicated for use in haemophilia A and B patients with inhibitors ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin ... A view shows the logo of ...

Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab ... It's the second drug in the TFPI class to be approved by the FDA after Pfizer's once ...

Moreover, Lilly’s tirzepatide injection products have been removed from the FDA’s drug shortage ... B with inhibitors. Alhemo is not approved in the United States. Novo Nordisk is trading ...

and Novo Nordisk’s Alhemo (concizumab). The FDA also gave its nod to Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), the first new class of antischizophrenia drug to be ...

The latest semaglutide (Ozempic; Novo Nordisk ... drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades. The approval of concizumab-mtci ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a ...